Literature DB >> 26407571

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Geoffrey I Shapiro1, Stewart McCallum2, Laurel M Adams3,4, Laurie Sherman5,2, Steve Weller6, Suzanne Swann7,2, Harold Keer8,9, Dale Miles9,10, Thomas Müller9,11, Daniel C Rabe12,13, Fabiola Cecchi14,13, Donald P Bottaro15, Patricia LoRusso16,17.   

Abstract

Entities:  

Year:  2015        PMID： 26407571     DOI： 10.1007/s10637-015-0287-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  2 in total

1.  Cabozantinib as a novel therapy for renal cell carcinoma.

Authors:  Ulka Vaishampayan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

2.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Authors:  Toni K Choueiri; Ulka Vaishampayan; Jonathan E Rosenberg; Theodore F Logan; Andrea L Harzstark; Ronald M Bukowski; Brian I Rini; Sandy Srinivas; Mark N Stein; Laurel M Adams; Lone H Ottesen; Kevin H Laubscher; Laurie Sherman; David F McDermott; Naomi B Haas; Keith T Flaherty; Robert Ross; Peter Eisenberg; Paul S Meltzer; Maria J Merino; Donald P Bottaro; W Marston Linehan; Ramaprasad Srinivasan
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.